See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Baseball
Natural Disasters
Social Media
Donald Trump
Trade War
Education
Stock Markets
Artificial Intelligence
US Economy
Property
Trade
Published • loading... • Updated

Translating Evidence to Clinical Practice: Oral SERDs in HR+/HER2– Metastatic Breast Cancer

Summary by onclive.com
On March 8, 2025, a select group of experts in breast cancer (BC) participated in a live workshop to discuss the place of oral selective estrogen receptor degraders (SERDs) in treating hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic BC (MBC). Moderated by Hope S. Rugo, MD, the discussion included the role of oral SERDs as monotherapy or in combination, the optimal integration of SERDs into standard-of-care therapies, and practical…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
targetedonc.comtargetedonc.com

Mitigating Toxicities With Oral SERDs and Other Breast Cancer Therapies

Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen agents in breast cancer.

Read Full Article
onclive.comonclive.com

Translating Evidence to Clinical Practice: Oral SERDs in HR+/HER2– Metastatic Breast Cancer

On March 8, 2025, a select group of experts in breast cancer (BC) participated in a live workshop to discuss the place of oral selective estrogen receptor degraders (SERDs) in treating hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic BC (MBC). Moderated by Hope S. Rugo, MD, the discussion included the role of oral SERDs as monotherapy or in combination, the optimal integration of SERDs into standard-of-care therapies, and practical…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

onclive.com broke the news in on Thursday, April 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Breast Cancer

Breast Cancer

Maryland

Maryland

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal